Diaceutics (LON:DXRX) Trading Up 0.8% – Still a Buy?

Diaceutics PLC (LON:DXRX)’s stock price traded up 0.8% during mid-day trading on Monday . The stock traded as high as GBX 128.25 ($1.67) and last traded at GBX 128.25 ($1.67). 58,412 shares were traded during mid-day trading, a decline of 54% from the average session volume of 126,544 shares. The stock had previously closed at GBX 127.20 ($1.65).

Analyst Ratings Changes

Several research firms have recently weighed in on DXRX. Canaccord Genuity Group reaffirmed a “buy” rating and set a GBX 160 ($2.08) price objective on shares of Diaceutics in a report on Tuesday, December 17th. Canaccord Genuity Group reaffirmed a “buy” rating and set a GBX 160 ($2.08) price objective on shares of Diaceutics in a report on Tuesday, December 17th.

Diaceutics Trading Up 0.8 %

The business’s 50-day moving average price is GBX 139.88 and its two-hundred day moving average price is GBX 130.55. The company has a market capitalization of £108.24 million, a P/E ratio of -38.04 and a beta of 0.58. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.85 and a quick ratio of 9.92.

Insider Buying and Selling

In other news, insider Graham Paterson acquired 11,643 shares of the stock in a transaction dated Thursday, January 30th. The shares were bought at an average cost of GBX 138 ($1.79) per share, for a total transaction of £16,067.34 ($20,869.39). 34.30% of the stock is currently owned by company insiders.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.